WO2023168329A3 - Novel prodrugs derived from nicotinic acid and ribose - Google Patents

Novel prodrugs derived from nicotinic acid and ribose Download PDF

Info

Publication number
WO2023168329A3
WO2023168329A3 PCT/US2023/063565 US2023063565W WO2023168329A3 WO 2023168329 A3 WO2023168329 A3 WO 2023168329A3 US 2023063565 W US2023063565 W US 2023063565W WO 2023168329 A3 WO2023168329 A3 WO 2023168329A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
nicotinic acid
ribose
novel prodrugs
prodrugs derived
Prior art date
Application number
PCT/US2023/063565
Other languages
French (fr)
Other versions
WO2023168329A2 (en
Inventor
G. Mani Subramanian
Gangadhara Ganapati
Manoj Chandrasinhji Desai
Nikhil Saji ZACHARIAH
Ajay KUMAR K S
Gautham Tumkur PRANESH
Original Assignee
Mitopower, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitopower, Inc. filed Critical Mitopower, Inc.
Priority to AU2023229381A priority Critical patent/AU2023229381A1/en
Priority to CN202380029760.2A priority patent/CN118922189A/en
Publication of WO2023168329A2 publication Critical patent/WO2023168329A2/en
Publication of WO2023168329A3 publication Critical patent/WO2023168329A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04—Phosphates; Phosphites; Polyphosphates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are novel prodrugs derived from nicotinic acid and pharmaceutical compositions thereof which may be used to treat or prevent a variety of medical disorders, which may be characterized by mitochondrial dysfunction. The compounds and pharmaceutical compositions thereof may be used to treat or prevent metabolic disorders, cardiovascular disorders, cerebrovascular disorders, liver disorders, a kidney disorders or muscle disorders.
PCT/US2023/063565 2022-03-02 2023-03-02 Novel prodrugs derived from nicotinic acid and ribose WO2023168329A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2023229381A AU2023229381A1 (en) 2022-03-02 2023-03-02 Novel prodrugs derived from nicotinic acid and ribose
CN202380029760.2A CN118922189A (en) 2022-03-02 2023-03-02 Novel prodrugs derived from niacin and ribose

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263315640P 2022-03-02 2022-03-02
US63/315,640 2022-03-02

Publications (2)

Publication Number Publication Date
WO2023168329A2 WO2023168329A2 (en) 2023-09-07
WO2023168329A3 true WO2023168329A3 (en) 2023-12-28

Family

ID=87851114

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/063565 WO2023168329A2 (en) 2022-03-02 2023-03-02 Novel prodrugs derived from nicotinic acid and ribose

Country Status (4)

Country Link
US (1) US20230279035A1 (en)
CN (1) CN118922189A (en)
AU (1) AU2023229381A1 (en)
WO (1) WO2023168329A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739117A (en) * 1993-10-22 1998-04-14 Fujimoto Pharmaceutical Co., Ltd. Agent for improving cerebral metabolism including glucose ester derivatives
WO2008106227A1 (en) * 2007-03-01 2008-09-04 Concourse Health Sciences Llc Isomers of inositol niacinate and uses thereof
WO2018033639A1 (en) * 2016-08-19 2018-02-22 The Queen's University Of Belfast Lactone intermediates of nicotinamide riboside and nicotinate riboside
WO2020131578A2 (en) * 2018-12-17 2020-06-25 Mitopower Llc Nicotinyl riboside compounds and their uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739117A (en) * 1993-10-22 1998-04-14 Fujimoto Pharmaceutical Co., Ltd. Agent for improving cerebral metabolism including glucose ester derivatives
WO2008106227A1 (en) * 2007-03-01 2008-09-04 Concourse Health Sciences Llc Isomers of inositol niacinate and uses thereof
WO2018033639A1 (en) * 2016-08-19 2018-02-22 The Queen's University Of Belfast Lactone intermediates of nicotinamide riboside and nicotinate riboside
WO2020131578A2 (en) * 2018-12-17 2020-06-25 Mitopower Llc Nicotinyl riboside compounds and their uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BHAGRATH, M ET AL.: "Improved delivery through biological membranes. Synthesis, characterization and antiviral activity of a series of ribavirin chemical delivery systems: 5' and carboxamide derivatives", ANTIVIRAL CHEMISTRY AND CHEMOTHERAPY, vol. 2, no. 5, 1991, pages 265 - 286, XP009019398 *
DEYRUP M., SIDWELL R., LITTLE R., DRUZGALA P., BODOR N., BREWSTER M. E.: "Improved Delivery through Biological Membranes. Synthesis and Antiviral Activity of a Series of Ribavirin Chemical Delivery Systems: 2′ and 3′ Derivatives", ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, ENGLAND, vol. 2, no. 6, 1 December 1991 (1991-12-01), England , pages 337 - 355, XP093124992, ISSN: 2040-2066, DOI: 10.1177/095632029100200603 *

Also Published As

Publication number Publication date
US20230279035A1 (en) 2023-09-07
AU2023229381A1 (en) 2024-08-29
WO2023168329A2 (en) 2023-09-07
CN118922189A (en) 2024-11-08

Similar Documents

Publication Publication Date Title
MX2021005047A (en) Substituted 6-azabenzimidazole compounds as hpk1 inhibitors.
PH12020551062A1 (en) 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
WO2019055966A3 (en) Pyridazinones and methods of use thereof
SA516380328B1 (en) substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol Compounds as targeting agentS oF ASGPR
TN2019000192A1 (en) Pyrazole derivatives as malt1 inhibitors
MX2018003331A (en) Administration of deuterated cftr potentiators.
PH12017502331A1 (en) 1,4-substituted piperidine derivatives
MX2017011951A (en) Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use.
ZA202200519B (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
WO2008064018A8 (en) Thienopyrimidinones for treatment of inflammatory disorders and cancers
EA201990904A1 (en) 1,3-DISPLACED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMOPOETIC PROSTAGLANDIN-D-SYNTHASE INHIBITORS
PH12020551501A1 (en) Oxadiazole transient receptor potential channel inhibitors
EA202092086A1 (en) ARGINASE INHIBITORS
WO2019226213A3 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
MX2020013699A (en) Pyrazole derivatives as malt1 inhibitors.
CR20200291A (en) Compositions and methods for the treatment of metabolic conditions
MX2020013899A (en) Pyrazole derivatives as malt1 inhibitors.
EP4342473A3 (en) Compounds useful in hiv therapy
SA520411783B1 (en) Condensed Imidazole Derivatives Substituted by Tertiary Hydroxy Groups as Pi3k-Gamma Inhibitorsrs
WO2019224790A3 (en) Prodrugs of fulvestrant
MX2022007171A (en) Cyclic compounds and methods of using same.
MX2022007275A (en) Compositions of bile acids and phenylbutyrate compounds.
WO2021113643A3 (en) Methods and compositions for synthesis of therapeutic nanoparticles
JOP20200133A1 (en) Process for preparing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid and its crystalline form for use as pharmaceutically active compound
WO2017053711A3 (en) Deuterated cftr potentiators

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23764123

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2023764123

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: AU23229381

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2023764123

Country of ref document: EP

Effective date: 20240814

ENP Entry into the national phase

Ref document number: 2023229381

Country of ref document: AU

Date of ref document: 20230302

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23764123

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 11202405822V

Country of ref document: SG

NENP Non-entry into the national phase

Ref country code: DE